• SGMD shareholder letter outlines building blocks of strategic vision
• Chan talks about two themes: geographic expansion for BudCars and Sugarmade’s move to cultivation operations
• BudCars is expanding into North San Francisco Bay area and wine country counties, then Los Angeles

In a letter to shareholders thanking them for their support, Sugarmade (OTCQB: SGMD) CEO Jimmy Chan outlined the “building blocks of a coherent and cohesive strategic vision” and noted that the company is putting in motion “key next steps to manifest that vision and drive strong and sustained shareholder value as a key emerging leader in the California cannabis marketplace” (https://ibn.fm/w96hm). 

“I want to highlight two themes that will help to drive our value proposition for shareholders over the intermediate term: geographic expansion for BudCars and our move to vertically integrate through the establishment of cultivation operations,” wrote Chan. “Together, they represent tangible catalysts driving both top and bottom line growth.”

In the letter, Chan noted that Sugarmade is working to “expand the scope, scale and reach of BudCars, a rapidly growing leader in the California cannabis delivery space — where we hold a 40% stake, with an option to take a controlling 70% stake, and where we are actively engaged in strategic and operational execution of the business.”

The letter outlined the dramatic growth BudCars has seen over the past six to eight months, noting that the company has consistently surpassed expectations in several key areas including customer acquisition and per-order volumes. “However, to fuel the next phase of our overarching vision, we must begin to expand our geographic reach,” Chan observed. 

“I have good news: that expansion is officially underway,” Chan continued. “We are expanding BudCars initially into the North San Francisco Bay Area and the Wine Country counties. That will be followed by our grand opening of BudCars Los Angeles, which we anticipate now will take place sometime in November.”

The letter noted that the move into the North Bay Wine Country area, which represents a more than doubling of the company’s total delivery territory, is “ripe with potential.” A recent “North Bay Business Journal” article reported that cannabis-related tax receipts from Sonoma County indicate that the area is seeing growth of 35% in the cannabis space. “As we begin to see tourism return in the wake of the global pandemic health crisis, we anticipate this region to represent one of the strongest bets as well, and we are excited about positioning BudCars to capitalize on that growth trend,” stated Chan.

The expansion into the wine country areas will be followed by the company’s grand opening in Los Angeles, slated for November. “Los Angeles is an enormous market for cannabis sales,” Chan explained. “It stands as perhaps the largest metropolitan cannabis marketplace on the planet. And we will be thrilled to see BudCars lay down roots and start taking market share in the area.”

The shareholder letter also noted that Sugarmade has secured a property zoned for cannabis cultivation and is working with regulators to move forward with plans to start its own cultivation operations. “This move will function to widen our margins on BudCars sales as well as to position Sugarmade to capitalize on growing demand in a chronically undersupplied marketplace,” the letter outlined. “Because of our access to end-market consumers through our BudCars distribution channel, we will also have an advantage over other cultivators in establishing a branded line of cannabis products, further supporting widening margins at each point in the chain.

“These are exciting times for Sugarmade. We have a rapidly growing business, and we are taking concrete steps now to build on that growth,” Chan concluded.

Sugarmade is a product and branding marketing company investing in operations and technologies with disruptive potential. The company’s brand portfolio includes CarryOutsupplies.com, SugarRush(TM) and Budcars.com. Sugarmade is an investor in BudCars and a joint operator of BudCars’ first operating location in Sacramento, California. 

During early 2020, Sugarmade gained a 40% stake in BudCars and in the Sacramento delivery operations via the acquisition of a 40% stake in Indigo Dye Group (Indigo). Under the terms of Sugarmade’s agreement with Indigo, Sugarmade also acquired an option to purchase an additional 30% interest in Indigo, upon the closing of which would provide Sugarmade with a 70% controlling interest. As of the date hereof, this option has not yet been exercised; Sugarmade’s stake in Indigo remains at 40%, and there is no assurance that Sugarmade will exercise the option to acquire an additional 30% interest in Indigo. 

However, since late May 2020, Sugarmade has been actively involved in development of Indigo’s operations with power to direct the activities and significantly impact Indigo’s economic performance. Sugarmade also has obligations to absorb losses and right to receive benefits from Indigo. As such, in accordance with the Financial Accounting Standards Board’s Accounting Standards Codification 810-10-25-38A through 25-38J, Indigo is considered a variable interest entity (“VIE”) of Sugarmade.

For more information, visit the company’s website at www.Sugarmade.com. 

NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://ibn.fm/SUGAR

• Pure Extracts Technologies specializes in extraction of key molecules, oils from biomass
• Extracts are used to manufacture THC & CBD oils, edibles, infused beverages
• Edible and infused beverage products have been available in Canada since late 2019, taking up 13% market share within Canada’s specialty drug market
• Pure Extracts recently awarded standard processing license by Health Canada, which will enable the Company to produce clinical trial samples in its purpose-built facilities located near Whistler, Canada

Pure Extracts Technologies, a Pemberton, British Columbia-domiciled private plant extraction company, has witnessed its fortunes rise as of late. The Company’s unique business model is founded on four key pillars, namely the extraction of key molecules and oils from biomass as a tolling service, white-label product formulation, manufacturing and sales of its own ‘Pure Pulls’ brand and sales of its new functional mushroom product line –  ‘Pure Mushrooms’. With the Canadian market for edibles and infused beverages alone estimated to amount to over $2 billion a year and rising  (https://ibn.fm/6CNsm), end product manufacturers have found themselves increasingly hard-pressed in establishing a reliable supply chain to satisfy their growing demand for raw materials. Pure Extracts in turn have found themselves ideally positioned to benefit from the ongoing explosion in demand.

Pure Extracts’ current operations combine the Company’s legacy cannabis and hemp tolling experience, which seeks to convert hemp biomass into extracts such as CBD oil, distillates and isolates, with a growing product development operation which has seen the Company white-label the production of vape pens & edible products for third party retailers. The Company has recently sought to broaden the scope of its product development business through the creation of its own-branded proprietary product portfolio, referred to as ‘Pure Pulls’, an initiative which has seen the Company create 34 separate formulations. Pure Extracts plans on distributing these formulations through a wide network of dispensaries located across Canada (https://ibn.fm/0JiGX). 

Canada’s specialty drug market has historically been dominated by dried flower products, with only an estimated 13% market share held by extract products (www.PureExtractsCorp.com/Investors), such as CBD oils or edibles. However, that has largely been a function of the Canadian extract market’s relatively nascent nature, with most products having only been legalized and made available to the wider public as of December 2019. Pure Extracts looks to consolidate a hold on the extract sector given the relative lack of incumbent producers while capitalizing on the abundance of biomass currently available in the market – a factor which has allowed the company to significantly lower its raw material costs and expand its extract margins. 

“Pure Extracts plans to position itself as an extraction industry leader in terms of its Full Spectrum Oil (‘FSO’) quality,” says CEO Ben Nikolaevsky. “We can’t wait to show our LP partners the incredible quality extracted oil that we can produce, be it for medicinal or recreational usage.”

The Company has also looked to raise the quality and general perception of their capabilities, a pursuit which has recently seen the Company awarded with a Standard Processing License by Health Canada under the Cannabis Act, following an extensive and meticulous five-month application and vetting process (https://ibn.fm/Q98aQ). Following the award of the Health Canada licence, Pure Extracts will now be able to begin producing products for the B-to-B market in their purpose-built, British Columbia-based, extraction facility while adhering to EU Good Manufacturing Practices (“GMP”). This in turn will help ensure that molecules will be extracted to the highest possible quality and qualify for international exports to Europe and the rest of the world.

“We are thrilled to be commencing production in our new, EU-GMP compliant, purpose-built facility and are confident that our state-of-the-art extraction and processing equipment will produce the highest quality cannabis and hemp derived oil available on the market,” said Pure Extracts founder and COO Doug Benville following the Health Canada License approval.

For more information, visit the company’s website at www.PureExtractsCorp.com. 

NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts are available in the company’s newsroom at http://ibn.fm/Pure

• The functional mushroom space has no clear leader, allowing for Rritual to target the role as the only premium brand currently on the market
• The company’s premium suite of products will be available first online through their website and the Amazon shop
• Rritual was the runner up for the Buyer’s Choice Award in the virtual ECRM presentation that connects companies with retail establishments creating business relationships
• The company was chosen for a special ECRM program on October 22, 2020, due to its award-winning status, connecting it to major retailers such as ALDI, Costco, Albertsons/Safeway, and Amazon
• The current functional food market is valued at more than $275 billion

Rritual Mushrooms is a private company that manufactures premium plant-based products including small-batch elixir powders and premium shots made from medicinal mushrooms and adaptogenic herbs. 

Rritual’s mission is to help each and every person meet the demands of modern life with style and ease through mushroom adaptogen products, slated to be sold online and through brick and mortar establishments. Through its management team, the company has developed connections with leading retailers and other establishments to begin rolling out its product offering. The first products will be available online through the Rritual website and an exclusive Amazon shop.

Recently, Rritual took part in a virtual program organized by ECRM, an international organization that connects suppliers and buyers. The virtual program, called “The Whole Body and Mind Wellness,” was the first time any ECRM program curated meetings related specifically to wellness lifestyle. Its goal was to connect major retailers with brands that support the growing consumer interest in health and fitness (https://ibn.fm/zAhLv). 

Rritual was selected as the runner up for the Buyers Choice Award for its Reishi Relax Elixir, picked by retail buyers from dozens of entries. “Retail buyers selected Rritual for the award because our packaging, design and formulation stood out amongst the dozens of products they evaluated,” CEO David Kerbel said. “Their stamp of approval on our product reinforces what we know: that Rritual products will capture the attention of shoppers on shelves and in e-comm, supporting our anticipated year-one growth.”

Due to this award, Rritual was invited to participate in a special ECRM program that took place on October 22, 2020. This event included major retailers such as ALDI, Costco, Albertsons/Safeway, and Amazon. 

Rich in polysaccharides, triterpenes, fatty acids, and amino acids, infused with Ashwagandha root to improve sleep quality and promote stress support, Reishi Relax is just one of the products included in Rritual’s premium suite. The other two leading products are Lion’s Mane Focus, paired with Rhodiola root to support cognitive function and overall brain health, and Chaga Immune, full of bioactive polysaccharides and infused with Eleuthero root to create an optimal environment for the body’s immune system.

The company is still in its early development stages, but it has the potential to become the leading force in the functional mushroom and foods market, amid a vacuum of premium brands in the space. The current functional food market is valued at more than $275 billion, with a global shift supporting wellness and the 7.9% CAGR forecast through 2025.

The demand for functional mushrooms is also forecasted to rise from $23 billion to an increase of $34 billion by 2024. Worldwide, the market is expected to reach $50 billion by 2025 due to the popularity of the superfood’s unique properties and the proven abilities to increase cognitive function, boost immunity, and help manage stress.

For more information, visit the company’s website at https://Investors.WeAreRritual.com. 

“Mental Fitness is a Daily Ritual”

NOTE TO INVESTORS: The latest news and updates relating to Rritual Mushrooms are available in the company’s newsroom at http://ibn.fm/Rritual 

• Mining district in Chile has been in sharp decline, hit particularly hard in 2020
• Government supports revitalization, has proposed a series of tax breaks for investors
• GOH drilling program anticipated to begin in January 2021

Formerly known as Altum Resources Corp, GoldHaven Resources (CSE: GOH) (OTCQB: ATUMF) is a Canadian junior exploration company active in the Maricunga Gold Belt of Northern Chile. The company has entered into agreements to acquire seven promising gold projects. The company’s goal is to identify and capitalize on valuable precious metal projects in mineral-rich districts with stable political jurisdictions. 

In April 2020, GoldHaven entered into an agreement to purchase the Rio Loa and the Coya projects. A few months later, in August, GOH entered into an agreement to acquire five potential gold projects in the same region of Northern Chile: the Alicia, Roma, Jacqueline, Valley and Condor projects.

The gold-rich Maricunga Belt, where all seven projects are located, straddles the border of Chile and Argentina. It is approximately 150 kilometers long and 30 kilometers wide. The mining district has seen a sharp decline over the last decade and has been hit particularly hard in 2020. 

According to an article in the “Northern Miner” (https://ibn.fm/nvvSj), new projects in the area could bring revitalization to the Chilean economy, which has suffered greatly due to the coronavirus pandemic. The government is supportive of these efforts and wants to see these new jobs created. A series of tax breaks for investors has been proposed that includes instant depreciation of capital investments begun by December 2022 and a tax credit worth 25% of the salary of each new job created. 

This government support of mining is not new. The Chilean Economic Development Agency launched an initiative over a decade ago to finance exploration projects in the country. A fund of $150 million was set aside to develop exploration and boost mining prosperity, with an end goal of becoming a world leader in the industry. To do so, the Chilean government began to promote investments that respected the environment, community and local workforce (https://ibn.fm/UM4kx). The government is looking for companies such as GoldHaven to come in and help revitalize the economy. 

GOH has identified four of its seven properties (the Rio Loa, Coya, Alicia and Roma projects) as high-priority targets and plans to begin its drilling program in January 2021. These targets were identified through mapping, geochemical sampling, satellite imagery and location relative to existing discoveries. 

For more information, visit the company’s website at www.GoldHavenResources.com.

NOTE TO INVESTORS: The latest news and updates relating to ATUMF are available in the company’s newsroom at http://ibn.fm/ATUMF 

• Mulch Manufacturing has signed mulch supplier contract with Vero Beach, Florida
• This — and other recent contracts — made possible due to SGTM’s recent completion of construction on its Florida Waste Management facility
• Sustainable Green Team was created by bringing together three industry-leading companies

Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, has announced that its wholly owned subsidiary will be the official mulch supplier for Vero Beach, Florida (https://ibn.fm/OunIk). Mulch Manufacturing has signed a one-year contract with the Florida city, with two additional one-year extensions. 

The Vero Beach contract is the most recent in a string of contracts awarded to Mulch Manufacturing, one of the largest producers of packaged mulch products in the country. Earlier this month, the company obtained mulch contracts from three Circle K convenient store divisions (https://ibn.fm/xBzrT). A week earlier the SGTM subsidiary landed a mulch and soil purchase agreement with the Kroger Co. to provide material for the 94 stories in its Louisville, Kentucky division (https://ibn.fm/s6yJf). And that contract came on the heels of the company being awarded a 2021 mulch packaging contract renewal from Menards Inc. (https://ibn.fm/Ek8QH).

“We are pleased to be awarded this new government contract opportunity,” said SGMT CEO and director Tony Raynor (https://ibn.fm/MTzQp). “And it’s all thanks to our recently completed construction in the Waste Management (‘WM’) facility in central Florida.” 

The July 2020 construction at the facility in Apopka, Florida, included a dual line mulch bagger and fully automated electric grinding screen operation. With the new fully electric equipment coming online, the company can increase its mulch production by four million bags per year within one shift. In addition, the new operations will allow full vertical integration at WM’s landfill by utilizing unused debris that is typically buried. Now the unused debris can be reused and branded into a premium mulch product onsite. 

“This is a pivotal advancement,” said Raynor commented. “With our strong relationship with Waste Management, we are progressing toward achieving true green sustainability.

Mulch Manufacturing is part of the Sustainable Green Team LTD, which was created by combining the resources of three companies that were leaders In their specialties: Mulch Manufacturing, National Storm Recovery and Central Florida Arbor Care. As a result, SGMT has the expertise to address the needs of each of the combined customers with a new level of quality and cost effectiveness.

The Sustainable Green Team, through its subsidiaries, provides tree services, debris hauling, and removal and bio-mass recycling, as well as manufacturing, packaging and sales of next-generation mulch products. The company’s primary corporate objective is to provide a solution for the treatment and handling of tree debris that is historically sent to local landfills and disposal sites, creating an environmental burden and pressure on disposal sites around the nation. 

To learn more about the Sustainable Green Team, view the company’s investor presentation at https://ibn.fm/vLpB2. For more information about Mulch Manufacturing, visit www.MulchMfg.com.

NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM 

• Backed by an anonymous donor, Berkeley launches a center for psychedelic science and public education
• Berkley follows examples of other notable universities such as Johns Hopkins in Maryland, Imperial College in London, and Canadian Centre for Psychedelic Science
• As an innovative company focusing on psilocybin, CYBIN is set to capitalize on growing academic, commercial attention

UC Berkeley is joining other prominent academic institutions, including Johns Hopkins University in Maryland and Imperial College in London, to accelerate the scientific research of psilocybin by launching a new center focusing on the compound (https://ibn.fm/CL4wX). As a mushroom life science company that expects to launch psilocybin-based products in jurisdictions where the substance is not prohibited, CYBIN Corp. will benefit from the growing research interest in psilocybin, bringing the compound to the mainstream. Five decades after a government ban on psychedelic research, UC Berkeley is opening its doors again to psychedelic science and public education. Supported by $1.25 million in seed funding from an anonymous donor, the prestigious university has announced the launch of the UC Berkeley Center for the Science of Psychedelics. The center aims to conduct research using psychedelics to explore cognition, perception, and emotion and their biological bases in the human brain. The center will also create a program to educate the public about the once-controversial and now rapidly advancing psychedelics research. “There’s never been a better time to start a center like this. The renewal of basic and clinical science with psychedelics has catalyzed interest among many people,” said UC Berkeley neuroscientist David Presti, who is also one of the center’s co-founders. Presti has teamed up with other co-founders to conduct studies and explore the potential of psilocybin and other psychedelic compounds. Their research will examine the effectiveness of treating highly prevalent mental disorders including anxiety, depression, post-traumatic stress disorder and substance abuse. Initial experimental studies will use psilocybin, the psychoactive compound found in “magic” mushrooms. “Some of these studies have produced striking results in cases that are otherwise resistant to more conventional medical treatment. This suggests that psychedelic compounds may offer new hope for people suffering from these disorders,” said UC Berkeley neuroscientist Michael Silver, who also serves as an inaugural director of the newly launched Center for the Science of Psychedelics. Likewise, Rotem Petranker, co-founder and director of the Canadian Centre for Psychedelic Science,is a clinical psychology PhD student with John Eastwood’s lab at York University (https://ibn.fm/be28y). His main research interests are sustained attention, emotional regulation and creativity, all of which are ostensibly affected by psychedelics. Petranker is passionate about establishing a rigorous framework for the study of psychedelics using open science principles. His clinical interests include disorders amenable to psychedelic psychotherapy, including mood disorders and OCD. Pretranker’s partner, co-founder and director Thomas Anderson, is a PhD candidate studying cognitive neuroscience at the University of Toronto in Canada. Anderson is a strong proponent of open science and publicly communicating scientific findings. Dedicated to supporting clinical studies across North America and other regions through strategic academic and institutional partnerships, including the Canadian Centre for Psychedelic Science, CYBIN Corp. is poised to benefit from the increasing research interest in psilocybin. As an early entrant into a rapidly growing field, CYBIN seems well positioned to leverage the growing recognition of psychedelic research leading to eventual public acceptance with the potential to propel the whole industry to the new level. CYBIN is an innovator in the stagnant pharmaceutical market, where it aims to become the first life science company to bring psiloybin medicine targeting major depressive disorder to market (https://ibn.fm/Y48W6). For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBIN are available in the company’s newsroom at http://ibn.fm/Cybin

• Knightscope recently named Ms. Mallorie Burak as Executive Vice President and Chief Financial Officer
• The company’s autonomous security robots use proprietary technology, combining robotics, self-driving capabilities, and artificial intelligence
• Game changing technology has now been in operation over 1 million hours and is operating across 5 time zones 24/7/365

Knightscope is a leader in the development of autonomous security capabilities. The company designs and builds Autonomous Security Robots (“ASRs”), which use Knightscope’s proprietary technology combining robotics, self-driving technologies, and artificial intelligence. The ASRs have proven to enhance the safety at hospitals, manufacturing plants, logistics facilities, schools, businesses, parking lots, and corporate campuses. This level of versatility enables Knightscope to disrupt the $500 billion security industry by offering reliable and cost-effective security solutions for a wide range of scenarios and locations – even during a pandemic. Knightscope currently has three models on the market, with one currently in long-term development – which all drive over 90 terabytes a year of data per machine to an intuitive browser-based user interface.

• K1 ASR – The K1 ASR is the 2018 Security Today New Product of the Year award winner. The K1 is a stationary indoor/outdoor unit that can be put in high-risk areas, lobby and reception areas, and parking lots. The K1 runs 24/7 and can be used at help and assistance points using the two-way intercom feature.
• K3 ASR – The K3 is an autonomously recharging indoor patrol ASR. The K3 is fully integrated with the Knightscope Security Operations Center (“KSOC”). Which makes it the smart eyes and ears of malls, warehouses, hospitals, offices, and several other locations where indoor patrol is optimal.
• K5 ASR – Primarily used outdoors, the K5 features the KSOC technology and autonomously recharges itself as well. It has been in operation for over 1 million hours and worked through its third winter, and still going strong.
• K7 ASR – The K7 is the latest ASR under development. This ASR is planned to handle rougher terrain, making it great for airports, utilities, federal government facilities, and many others. The ASR is also planned to be fully integrated with the KSOC user interface technology.
• KSOC – the Knightscope Security Operations Center (“KSOC”) is the browser-based user interface our clients utilize to have the magic of our technology at their fingertips.

Providing real-time access to data around the clock, KSOC also features 360-degree eye-level HD video streaming, people detection, facial recognition, automatic license plate recognition, thermal anomaly detection, and automatic signal detection. The technology is also available to schedule patrols, maintain autonomous charging, analytics, live audio broadcast, two-way intercom, pre-recorded broadcast messages, and the capability to conduct investigations as well as obtain court admissible evidence. Since Knightscope’s inception, it has raised over $70 million with over 16,000 investors. In preparation for a potential public listing, the company is in the process of raising an additional $25 million. It has already reserved the NASDAQ ticker symbol “KSCP.” The company recently appointed Ms. Mallorie Burak as Executive Vice President and Chief Financial Officer. Ms. Burak is an experienced financial executive with over 25 years of expertise in many industries that range from early-stage start-ups to multi-national corporations.  Ms. Burak’s previous experience includes CFO for ThinFilms Electronics ASA and many other industry leaders in which she held the CFO title. She has a proven track record of creating a high-performing culture with a focus on operational excellence (https://ibn.fm/ANhi2). Knightscope’s core mission is to make the United States of America the safest nation in the world. Through its innovative, proprietary technology, the company plans on supporting the millions of law enforcement and security professionals across the country. For more information, visit the company’s website at www.Knightscope.com NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• Study results have exciting therapeutic potential across wide range of CNS indications.
• VTGN focused on developing new generation of medications to treat anxiety, depression and more.
• Company committed to finding treatment to help estimated 264 million people around the world who suffer from depression.

Noting that 17.3 million adults in the United States have had at least one major depressive episode and some 264 million people around the world suffer from depression, VistaGen Therapeutics (NASDAQ: VTGN) is committed to finding effective treatments for depression that reach beyond the current standard of care, which includes oral antidepressants and oral atypical antipsychotics. The company has released data from a second preclinical study of its oral investigational drug, AV-101, in combination with probenecid. The results, which complement findings from a prior preclinical study, indicate that AV-101, when combined with probenecid, substantially increased the brain concentration of its active metabolite, 7-Cl-KYNA, a potent and selective full antagonist of the N-methyl-D-aspartate receptor (NMDAr) glycine co-agonist site. The combination of drugs may therefore reduce rather than block NMDAr signaling—an effect which could carry significant therapeutic potential. “These new positive results amplify our message that AV-101, when administered in combination with probenecid, has exciting therapeutic potential across a wide range of CNS (central nervous system) indications,” said VistaGen CEO Shawn Singh. “The studies completed to date are promising and will help us determine the best next step in our overall development plan for the combination.” VistaGen is assessing the potential of the AV-101/probenecid combination as a treatment for multiple CNS disorders, including dyskinesia (unwanted movement) associated with levodopa therapy for Parkinson’s disease, epilepsy, major depressive disorder, neuropathic pain and suicidal ideation (thoughts and behaviors).The company’s efforts currently are focused on developing three new generation medicines for anxiety, depression and other CNS disorders where the current standard of care is inadequate, resulting in high unmet need. Each of VistaGen’s three drug candidates, AV-101, PH10 and PH94B, has a differentiated mechanism of action, an exceptional safety profile in all studies to date and therapeutic potential in multiple CNS markets. For more information, visit the company’s website at www.VistaGen.com. NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

• Houston-based CNS Pharmaceuticals is preparing to launch Phase 2 clinical testing of a novel brain cancer-fighting drug candidate called Berubicin early next year
• The biopharmaceutical company recently announced that a U.S.-based company contracted to make Berubicin has completed its production process and an Italian company working on a dual track in Europe is expected to finish by the end of the year
• Berubicin has shown promise in combatting Glioblastoma multiforme, an aggressive form of brain cancer commonly regarded as incurable. One participant in Berubicin’s Phase 1 trial remains cancer-free 14 years after the trial
• CNS Pharmaceuticals, with its sublicensee partner WPD Pharmaceuticals, is also preparing for 2 clinical trials in Poland including the first Phase 1 pediatric trial of Berubicin and a parallel Phase 2 trial in adults

The U.S. manufacturer for a novel anthracycline being tested by biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP) as a potential new strategy in combatting an inexorable and ultimately fatal type of brain tumor has completed the manufacturing process for the drug candidate, known as Berubicin. CNS Pharmaceutical engaged Pharmaceutics International, Inc. (“Pii”) to make Berubicin in the United States while BSP Pharmaceuticals S.p.A. (“BSP“) worked on a dual track to make Berubicin in Italy under the company’s strategy of supplying its upcoming Phase 2 trials with sufficient quantities of the orphan drug status product amid the risk of delays in production and shipping as a result of the ongoing COVID-19 pandemic. Completion of both Pii’s and BSP’s manufacturing of Berubicin moves CNS Pharmaceuticals closer to completing its preparations for filing an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) to fight glioblastoma. Glioblastoma multiforme (“GBM”) is an aggressive brain cancer that has no known cure, however the Phase 1 trial of Berubicin in 2006 produced some promising results. Of 25 trial participants who were evaluated, 44 percent achieved what the company refers to as “statistically significant improvement in clinical benefit” (https://ibn.fm/tOnAN) while one patient has remained completely cancer-free as of the last evaluation on Feb. 20 — some 14 years after the initial trial phase. Glioblastoma patients have a median survival rate of only 14.6 months from the date of the malignancy’s diagnosis, although the drug temozolomide has been shown effective in temporarily extending the lifespan of fewer than 40 percent of the GBM patients with a specific genetic variation. The persistent cancer tends to recur after surgery and to develop a resistance to temozolomide over time, making an effective therapy in treating it an attractive goal. The orphan drug designation grants Berubicin certain benefits during its development and provides CNS with the potential for market exclusivity if the drug is approved for combatting malignant gliomas. “We are extremely pleased to achieve yet another milestone in our preparation efforts and demonstrate our continued ability to execute upon both our operational and clinical strategies in a timely and proficient manner,” CEO John Climaco stated in the news release. “We remain committed to further progressing our trial preparations, as we look forward to initiating a U.S. Phase 2 trial for Berubicin during the first quarter of 2021.” As further evidence of the company’s progress toward advancing its clinical testing, CNS has contracted with Worldwide Clinical Trials as the research organization, Image Analysis Group as the imaging partner and with Berry Consultants as a biostatistical adviser for its Phase 2 trial design. CNS has also added renowned neuro-oncologist Dr. Patrick Wen to its Scientific Advisory Board. For more information, visit the company’s website at www.CNSPharma.com NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• One of few uranium, natural resource companies in North America with no debt
• Sets stage for increasing uranium production as markets improve; launching rare earth element initiative
• Allows rare earth production as markets warrant
• Applauds U.S. government for securing agreement to limit imports of uranium from Russia

Energy Fuels (NYSE American: UUUU) (TSX: EFR), the leading uranium mining company in the United States, has officially reached debt-free status, a goal it has been working toward for the past several months (https://ibn.fm/BFes9). The company reached that goal following the retirement of its remaining Cdn$10.4 million of floating rate convertible unsecured subordinated debentures; the company currently has no other remaining short- or long-term debt. “While many uranium and other natural resource companies have significant debt burdens, Energy Fuels is proud to announce that today we became debt free,” Energy Fuels president and CEO Mark S. Chalmers stated. “Being debt-free distinguishes Energy Fuels not only from many of our peers in the uranium and natural resource sectors but also from many public companies in general. Having no debt reduces costs and allows Energy Fuels to better weather market volatility. Coupled with our strong working capital position, this also provides us with a ‘clean slate’ from which to increase uranium production when warranted and to launch the exciting rare earth element initiative we are pursuing.” Energy Fuel offers a truly unique portfolio that includes more licensed and constructed production capacity, mines and in-ground uranium resources than any other producer in the United States. The company has also developed diverse cash-flow-generating opportunities, including vanadium production and uranium recycling. And the company is making excellent commercial and technical progress on rare earth element processing. “We have a number of opportunities in front of us right now, any one of which could result in significant cash flows for the company,” Chalmers said. “Critical minerals, including uranium, rare earth elements and vanadium, are front and center in the U.S. right now, including bipartisan support in the U.S. government. We are continuing to work with our allies in the administration and Congress to create a strategic U.S. uranium reserve to enhance national security and energy security. As the leading uranium miner in the U.S., with more production facilities, capacity, expertise and in-ground resources than any other U.S. uranium producer, we expect to be one of the prime beneficiaries of any U.S. government support.” Chalmers also stated that the company was pleased that the U.S. Department of Commerce was able to reduce uranium and nuclear fuel imports into the U.S. from Russia over the long term. “President Trump’s executive orders on critical minerals . . .  may be an important step toward the U.S. government providing tangible support and/or funding to producers and processors of critical minerals, including the uranium and vanadium we currently produce, and the rare earth elements we hope to produce in the future,” Chalmers said. “And of course, global uranium markets, where spot prices are up over 20% this year, appear poised to continue their bounce back, due to significant global production cutbacks and the fact that current spot and term pricing cannot sustain new or existing primary supply,” he continued. “Energy Fuels has created a number of significant, potentially ‘game-changing,’ catalysts while also maintaining a strong working capital position and eliminating debt. We look forward to continuing to provide updates in the coming weeks and months on several of these initiatives.” Based in Lakewood, Colorado, Energy Fuels holds three of America’s key uranium production centers: the Nichols Ranch (“ISR”) project in Wyoming, the Alta Mesa ISR Project in Texas and the White Mesa Mill in Utah — the only conventional uranium mill operating in the United States today. Together these assets have a licensed capacity of more than 11.5 million pounds of U3O8 per year. With an asset portfolio that boasts more uranium production facilities, in-ground resources, production capacity and experienced personnel than any other producer, Energy Fuels is in a unique position to maintain its position as the leading producer of uranium in an era where the U.S. energy industry is moving toward zero-carbon sources of electricity, including nuclear. For more information, visit the company’s website at www.EnergyFuels.com. NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU